Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study

被引：5

作者：

Agarwal, N. ^{[1
]}

Brugarolas, J. ^{[2
]}

Ghatalia, P. ^{[3
]}

George, S. ^{[4
]}

Haanen, J. B. A. G. ^{[5
]}

Gurney, H. P. ^{[6
]}

Ravilla, R. ^{[7
]}

Van der Veldt, A. A. M. ^{[8
]}

Beuselinck, B. ^{[9
]}

Pokataev, I. ^{[10
]}

Suelmann, B. B. ^{[11
]}

Tuthill, M. ^{[12
]}

Vaena, D. ^{[13
]}

Zagouri, F. ^{[14
]}

Wu, J. ^{[15
]}

Liu, Y. ^{[15
]}

Perini, R. ^{[15
]}

Merchan, J. R. ^{[16
]}

Atkins, M. B. ^{[17
]}

机构：

[1] Huntsman Canc Inst, Oncol Internal Med Dept, Salt Lake City, UT USA

[2] Univ Texas Southwestern Med Ctr, Internal Med Hematol Oncol, Dallas, TX USA

[3] Fox Chase Canc Ctr, Hematol Oncol, Philadelphia, PA USA

[4] Roswell Pk Canc Inst, Oncol, Buffalo, NY USA

[5] Netherlands Canc Inst, Oncol, Amsterdam, Netherlands

[6] Macquarie Univ, Oncol, Sydney, NSW, Australia

[7] Albany Canc Ctr, Oncol, New York Oncol Hematol, Albany, NY USA

[8] Erasmus MC, Oncol, Rotterdam, Netherlands

[9] UZ Leuven, Oncol, Leuven, Belgium

[10] City Clin Oncol Hosp 1, Oncol, Moscow, Russia

[11] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands

[12] Oxford Univ Hosp NHS Fdn Trust, Oncol & Hematol, London, England

[13] West Canc Ctr & Res Inst, Oncol, Germantown, TN USA

[14] Alexandra Reg Gen Hosp, Oncol, Athens, Greece

[15] Merck & Co Inc, Oncol, Rahway, NJ USA

[16] Univ Miami Hosp & Clin, Oncol, Sylvester Canc Ctr, Canc Res Serv, Miami, FL USA

[17] Georgetown Univ, Oncol, Med Ctr, Washington, DC USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1881O

引用

页码：S1011 / S1011

页数：1

共 50 条

[1] Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
Agarwal, N.
Brugarolas, J.
Ghatalia, P.
George, S.
Haanen, J. B.
Gurney, H.
Ravilla, R.
van der Veldt, A.
Beuselinck, B.
Pokataev, I.
Suelmann, B. B. M.
Tuthill, M. H.
Vaena, D.
Zagouri, F.
Wu, J.
Perini, R. F.
Liu, Y.
Merchan, J.
Atkins, M. B.
ANNALS OF ONCOLOGY, 2024, 35 (12) : 1148 - 1156
[2] Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study
Atkins, Michael B.
Ghatalia, Pooja
Merchan, Jaime R.
George, Saby
Haanen, John
Gurney, Howard
Ravilla, Rahul
Van Der Veldt, Astrid Aplonia Maria
Beuselinck, Benoit
Pokataev, Ilya
Suelmann, Britt
Tuthill, Mark H.
Vaena, Daniel A.
Zagouri, Flora
Lin, Jianxin
Perini, Rodolfo F.
Liu, Yanfang
Brugarolas, James
Agarwal, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] The randomized phase 1/2 LITESPARK-024 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma (RCC)
McDermott, David F.
Peer, Avivit
Agarwal, Neeraj
Atkins, Michael B.
Cornell, Jerry
Perini, Rodolfo F.
Grossmann, Kenneth F.
Gurney, Howard
CANCER RESEARCH, 2023, 83 (08)
[4] LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).
McDermott, David F.
Peer, Avivit
Agarwal, Neeraj
Atkins, Michael B.
Cornell, Jerry
Perini, Rodolfo F.
Grossmann, Kenneth F.
Gurney, Howard
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Phase 1 LITESPARK-001 study of belzutifan in advanced solid tumors: Results of the glioblastoma cohort
Strowd, Roy E.
De La Fuente, Macarena Ines
Bauer, Todd Michael
Papadopoulos, Kyriakos P.
Chen, Ke
Perini, Rodolfo F.
Liu, Yanfang
McDermott, David F.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma.
McDermott, David F.
Peer, Avivit
Agarwal, Neeraj
Atkins, Michael B.
Cornell, Jerry
Perini, Rodolfo F.
Grossmann, Kenneth F.
Gurney, Howard
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[7] Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003
Choueiri, T. K.
Bauer, T.
Merchan, J.
Figlin, R.
Roy, A.
Perini, R.
Vickery, D.
Arrowsmith, E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
[8] Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003
McDermott, D. F.
Choueiri, T. K.
Tykodi, S.
Merchan, J.
Roy, A.
Perini, R.
Vickery, D.
Bauer, T.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1208 - +
[9] Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
Powles, Thomas
Albiges, Laurence
Jalkanen, Katriina Johanna
De Velasco, Guillermo
Burotto, Mauricio
Ghatalia, Pooja
Suarez, Cristina
Lam, Elaine T.
Iacovelli, Roberto
Gumus, Mahmut
Verzoni, Elena
Kollmannsberger, Christian K.
Stadler, Walter Michael
Venugopal, Balaji
Shinde, Reshma
Saretsky, Todd L.
He, Li
Vickery, Donna
Choueiri, Toni K.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 361 - 361
[10] Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
Choueiri, T. K.
Bauer, T.
Merchan, J. R.
McDermott, D. F.
Figlin, R.
Arrowsmith, E.
Michaelson, M. D.
Heath, E.
D'Souza, A. A.
Zhao, S.
Mhamdi, L.
Perini, R.
Vickery, D.
Tykodi, S.
ANNALS OF ONCOLOGY, 2023, 34 : S1328 - S1329

← 1 2 3 4 5 →